p21(waf1/cip1) and transforming growth factor β1 protein expression correlate with survival in non-small cell lung cancer

Clinical Cancer Research

Volumn 4, Issue 6, 1998, Pages 1499-1506

  Bennett, William P ^a,h   El Deiry, Wafik S ^b   Rush, Walter L ^f   Guinee Jr , Donald G ^c   Freedman, Andrew N ^a   Caporaso, Neil E ^a   Welsh, Judith A ^a   Jones, Raymond T ^d   Borkowski, Andrew ^e   Travis, William D ^f   Fleming, Marian V ^f   Trastek, Victor ^g   Pairolero, Peter C ^g   Tazelaar, Henry D ^g   Midthun, David ^g   Jett, James R ^g   Liotta, Lance A ^a   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e BALTIMORE VA MEDICAL CENTER   (United States)

^f ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^g MAYO CLINIC   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P21; TRANSFORMING GROWTH FACTOR BETA1; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; ENZYME INHIBITOR; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TUMOR SUPPRESSOR GENE; BIOSYNTHESIS; CANCER STAGING; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; LUNG TUMOR; MALE; MORTALITY; MUTATION; PATHOLOGY; SEXUAL DEVELOPMENT; SURVIVAL; TIME;

CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE-FREE SURVIVAL; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MUTATION; NEOPLASM STAGING; PROGNOSIS; SEX CHARACTERISTICS; SURVIVAL ANALYSIS; TIME FACTORS; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031596391     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
2. El-Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., and Wang, Y. WAF1/CIP1 is induced in p53-mediated G, arrest and apoptosis. Cancer Res., 54: 1169-1174, 1994.
3. Halevy, O., Novitch, B. G., Spicer, D. B., Skapek, S. X., Rhee, J., Hannon, G. J., Beach, D., and Lassar, A. B. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science (Washington DC), 267: 1018-1021, 1995.
4. Datto, M. B., Yu, Y., and Wang, X. F. Functional analysis of the transforming growth factor β responsive elements in the WAF1/Cip1/ p21 promoter. J. Biol. Chem., 270: 28623-28628, 1995.
5. WAF1/CIP1 expression. Nat. Genet., 15: 78-82, 1997.
6. waf1/cip1 expression by p53-independent pathways. Oncogene, 12: 1557-1564, 1996.
7. Russo, T., Zambrano, N., Esposito, F., Ammendola, R., Cimino, F., Fiscella, M., Jackman, J., O'Connor, P. M., Anderson, C. W., and Appella, E. A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. J. Biol. Chem., 270: 29386-29391, 1995.
8. Michieli P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E., and Givol D. Induction of WAF1/CIP1 by a P53-independent pathway. Cancer Res., 54: 3391-3395, 1994.
9. WAF-1/CIP1 during differentiation. Oncogene, 9: 3389-3396, 1994.
10. 1 arrest in UV-irradiated human skin fibroblasts. Cancer Res., 57: 3390-3394, 1997.
11. Li, Y., Jenkins, C. W., Nichols, M. A., and Xiong, Y. Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21. Oncogene, 9: 2261-2268, 1994.
12. waf1/cip1 expression. Biochem. Biophys. Res. Commun., 227: 564-569, 1996.
13. Zhang, H., Hannon, G. J., Casso, D., and Beach, D. p21 is a component of active cell cycle kinases. Cold Spring Harbor Symp. Quant. Biol., 59: 21-29, 1994.
14. Cip1 in muscle and other terminally differentiating cells. Science (Washington DC), 267: 1024-1027, 1995.
15. Macleod, K. F., Sherry, N., Hannon, G., Beach, D., Tokino, T., Kinzler, K., Vogelstein, B., and Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev., 9: 935-944, 1995.
16. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55: 2910-2919, 1995.
17. sdi1/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene, 10: 835-840, 1995.
18. cip1/waf1 gene in normal diploid human fibroblasts. Science (Washington DC), 277: 831-834, 1997.
19. Wang, J., and Walsh, K. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation. Science (Washington DC), 273: 359-361, 1996.
20. Polyak, K., Waldman, T., He, T. C., Kinzler, K. W., and Vogelstein, B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev., 10: 1945-1952, 1996.
21. WAF1. Cancer Res., 55: 4536-4539, 1995.
22. WAF1/Cip1 pathway in human thyroid cells. Cancer Res., 55: 2075-2080, 1995.
23. Dulic, V., Kaufmann, W. K., Wilson, S. J., Tlsty, T. D., Lees, E., Harper, J. W., Elledge, S. J., and Reed, S. I. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell, 76: 1013-1023, 1994.
24. Yingling, J. M., Wang, X. F., and Bassing, C. H. Signaling by the transforming growth factor-β receptors. Biochim. Biophys. Acta, 1242: 115-136, 1995.
25. Lin, H. Y., and Moustakas, A. TGF-β receptors: structure and function. Cell. Mol. Biol., 40: 337-349, 1994.
26. Riggins, G. J., Thiagalingam, S., Rozenblum, E., Weinstein, C. L., Kern, S. E., Hamilton, S. R., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., and Vogelstein, B. Mad-related genes in the human. Nat. Genet., 13: 347-349, 1996.
27. Riggins, G. J., Kinzler, K. W., Vogelstein, B., and Thiagalingam, S. Frequency of Smad gene mutations in human cancers. Cancer Res., 57: 2578-2580, 1997.
28. Li, C. Y., Suardet, L., and Little, J. B. Potential role of WAF1/ Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. J. Biol. Chem., 270: 4971-4974, 1995.
29. waf1/cip1 and the control of cell proliferation. In: N. S. B. Thomas (ed.), Cell Cycle Control and Apoptosis in Malignant Disease, pp. 55-75. Oxford, UK: Bios Scientific Publishers, 1996.
30. Iavarone, A., and Massague, J. Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-β in cells lacking the CDK inhibitor p15. Nature (Lond.), 387: 417-422, 1997.
31. Havrilesky, L. J., Hurteau, J. A., Whitaker, R. S., Elbendary, A., Wu, S., Rodriguez, G. C., Bast, R. C., Jr., and Berchuck, A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β. Cancer Res., 55: 944-948, 1995.
32. Jurgensmeier, J. M., Schmitt, C. P., Viesel, E., Hofler, P., and Bauer, G. Transforming growth factor β-treated normal fibroblasts eliminate transformed fibroblasts by induction of apoptosis. Cancer Res., 54: 393-398, 1994.
33. Taetle, R., Payne, C., Dos Santos, B., Russell, M., and Segarini, P. Effects of transforming growth factor β1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res., 53: 3386-3393, 1993.
34. Hsing, A. Y., Kadomatsu, K., Bonham, M. J., and Danielpour, D. Regulation of apoptosis induced by transforming growth factor β1 in nontumorigenic rat prostatic epithelial cell lines. Cancer Res., 56: 5146-5149, 1996.
35. Guinee, D. G., Jr., Travis, W. D., Trivers, G. E., De Benedetti, V. M., Cawley, H., Welsh, J. A., Bennett, W. P., Jett, J., Colby, T. V., Tazelaar, H., Abbondanzo, S. L., Pairolero, P., Trastek, V., Caporaso, N. E., Liotta, L. A., and Harris, C. C. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. Carcinogenesis (Lond.), 16: 993-1002, 1995.
36. Harty, L. C., Guinee, D. G., Jr., Travis, W. D., Bennett, W. P., Jett, J., Colby, T. V., Tazelaar, H., Trastek, V., Pairolero, P., Liotta, L., Harris, C. C., and Caporaso, N. E. p53 mutations and occupational exposures in a surgical series of lung cancers. Cancer Epidemiol. Biomark. Prev., 5: 997-1003, 1996.
37. Fleming, M. V., Guinee, D. G., Chu, W. S., Caporaso, N. E., Bennett, W. P., Jett, J., Abbondanzo, S. L., Colby, T., Tazelaar, H., Pairolero, P., Trastek, V., Liotta, L., Harris, C. C., and Travis, W. D. Bcl-2 immunohistochemistry in a surgical series of lung cancer patients. Hum. Pathol., 29: 60-64, 1998.
38. Przygodzki, R. M., Khan, M. A., Guinee, D. G., Bennett, W. P., Shields, P. G., Travis, W. D., Jett, J., Colby, T., Tazelaar, H., Pairolero, P., Trastek, V., Liotta, L., Harris, C. C., and Caporaso, N. E. Analysis of cancer susceptibility markers GSTM1, CYP1A1, CYP2E1, in correlation to p53 mutation spectrum, in the NCI-Mayo Clinic lung cancer study. Pharmacogenetics, in press, 1998.
39. Reiss, M., and Barcellos-Hoff, M. H. Transforming growth factor-β in breast cancer: a working hypothesis. Breast Cancer Res. Treat., 45: 81-95, 1997.
40. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X. F. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA, 92: 5545-5549, 1995.
41. Serra, R., and Moses, H. L. Tumor suppressor genes in the TGF-β signaling pathway? Nat. Med., 2: 390-391, 1996.
42. Koli, K. M., Ramsey, T. T., Ko, Y., Dugger, T. C., Brattain, M. G., and Arteaga, C. L. Blockade of transforming growth factor-β signaling does not abrogate antiestrogen-induced growth inhibition of human breast carcinoma cells. J. Biol. Chem., 272: 8296-8302, 1997.
43. Elbendary, A., Berchuck, A., Davis, P., Havrilesky, L., Bast. R. C., Jr., Iglehart, J. D., and Marks, J. R. Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ., 5: 1301-1307, 1994.
44. Akagi, M., Yasui, W., Akama, Y., Yokozaki, H., Tahara, H., Haruma, K., Kajiyama, G., and Tahara, E. Inhibition of cell growth by transforming growth factor β1 is associated with p53-independent induction of p21 in gastric carcinoma cells. Jpn. J. Cancer Res., 87: 377-384, 1996.
45. Hsu, S., Huang, F., Hafez, M., Winawer, S., and Friedman, E. Colon carcinoma cells switch their response to transforming growth factor β1 with tumor progression. Cell Growth Differ., 5: 267-275, 1994.
46. Huang, F., Newman, E., Theodorescu, D., Kerbel, R. S., and Friedman, E. Transforming growth factor β1 (TGF-β1) is an autocrine-positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF-β1 antisense expression plasmid. Cell Growth Differ., 6: 1635-1642, 1995.
47. WAF1/CIP1 induces growth arrest, giant cell formation and apoptosis in human breast carcinoma cell lines. Oncogene, 11: 1899-1905, 1995.
48. Fan, G., Ma, X., Kren, B. T., and Steer, C. J. The retinoblastoma gene product inhibits TGF-β1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene, 12: 1909-1919, 1996.
49. waf1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res., 2: 1591-1599, 1996.
50. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br. J. Cancer, 74: 208-215, 1996.
51. Byrne, R. L., Home, C. H., Robinson, M. C., Autzen, P., Apakama, I., Bishop, R. I., Neal, D. E., and Hamdy, F. C. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br. J. Urol., 79: 190-195, 1997.
52. Wang, A., Yoshimi, N., lno, N., Tanaka, T., and Mori, H. WAF1 expression and p53 mutations in human colorectal cancers. J. Cancer Res. Clin. Oncol., 123: 118-123, 1997.
53. Thor, A. D., and Yandell, D. W. Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. J. Natl. Cancer Inst., 85: 176-177, 1993.
54. Passlick, B., Izbicki, J. R., Riethmuller, G., and Pantel, K. p53 in non-small cell lung cancer. J. Natl. Cancer Inst., 86: 801-803, 1994.
55. Volm, M., and Mattem, J. Immunohistochemical detection of p53 in non-small cell lung cancer. J. Natl. Cancer Inst., 86: 1249, 1994.
56. Lee, J. S., Yoon, A., Kalapurakal, S. K., Ro, J. Y., Lee, J. J., Tu, N., Hittelman, W. N., and Hong, W. K. Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J. Clin. Oncol., 13: 1893-1903, 1995.
57. Passlick, B., Izbicki, J. R., Haussinger, K., Thetter, O., and Pantel, K. Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 109: 1205-1211, 1995.
58. Morkve, O., Halvorsen, O. J., Skjaerven, R., Stangeland, L., Gulsvik, A., and Laerum, O. D. Prognostic significance of p53 protein expression and DNA ploidy in surgically treated non-small cell lung carcinomas. Anticancer Res., 13: 571-578, 1993.
59. Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Chine, S., Angeletti, C. A., and Bevilacqua, G. Recurrence and death in non-small cell lung carcinomas: a prognostic model using pathological parameters, microvessel count, and gene protein products. Clin. Cancer Res., 2: 1067-1075, 1996.
60. Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., and Shirakusa, T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small cell lung cancer. J. Natl. Cancer Inst., 85: 2018-2023, 1993.
61. Fujino, M., Dosaka-Akita, H., Harada, M., Hiroumi, H., Kinoshita, I., Akie, K., and Kawakami, Y. Prognostic significance of p53 and ras p21 expression in non-small cell lung cancer. Cancer (Phila.), 76: 2457-2463, 1995.
62. Esposito, V., Baldi, A., De Luca, A., Micheli, P., Mazzarella, G., Baldi, F., Caputi, M., and Giordano, A. Prognostic value of p53 in non-small cell lung cancer: relationship with proliferating cell nuclear antigen and cigarette smoking. Hum. Pathol., 28: 233-237, 1997.
63. Carbone, D. P., Mitsudomi, T., Chiba, I., Piantadosi, S., Rusch, V., Nowak, J. A., McIntire, D., Slamon, D., Gazdar, A., and Minna, J. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest, 106: 377S-381S, 1994.
64. Quinlan, D. C., Davidson, A. G., Summers, C. L., Warden, H. E., and Doshi, H. M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res., 52: 4828-4831, 1992.
65. Isobe, T., Hiyama, K., Yoshida, Y., Fujiwara, Y., and Yamakido, M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn. J. Cancer Res., 85: 1240-1246, 1994.
66. Ebina, M., Steinberg, S. M., Mulshine, J. L., and Linnoila, R. I. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res., 54: 2496-2503, 1994.
67. Horio, Y., Takahashi, T., Kuroishi, T., Hibi, K., Suyama, M., Niimi, T., Shimokata, K., Yamakawa, K., Nakamura. Y., and Ueda, R. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res., 53: 1-4, 1993.
68. McLaren, R., Kuzu, I., Dunnill, M., Harris, A., Lane, D., and Gatter, K. C. The relationship of p53 immunostaining to survival in carcinoma of the lung. Br. J. Cancer, 66: 735-738, 1992.
69. Volm, M., Efferth, T., and Mattern, J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res., 12: 11-20, 1992.
70. Langendijk, J. A., Thunnissen, F. B., Lamers, R. J., de Jong, J. M., ten Velde, G. P., and Wouters, E. F. The prognostic significance of accumulation of p53 protein in stage III non-small cell lung cancer treated by radiotherapy. Radiother. Oncol., 36: 218-224, 1995.
71. Lohmann, D., Putz, B., Reich, U., Bohm, J., Prauer, H., and Hofler, H. Mutational spectrum of the p53 gene in human small-cell lung cancer and relationship to clinicopathological data. Am. J. Pathol., 142: 907-915, 1993.
72. DiGiuseppe, J. A., Redston, M. S., Yeo, C. J., Kern, S. E., and Hruban, R. H. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am. J. Pathol., 147: 884-888, 1995.
73. Marchetti, A., Doglioni, C., Barbareschi, M., Buttitta, F., Pellegrini, S., Bertacca, G., Chella, A., Merlo. G., Angeletti, C. A., Palma, P D and Bevilacqua, G. p21 RNA and protein expression m non-small cell lung carcinomas: evidence of P53-independent expression and association with tumoral differentiation. Oncogene, 12: 1319-1324, 1996.
74. Elbendary, A. A., Cirisano, F. D., Evans, A. C., Jr., Davis, P. L., Iglehart, J. D., Marks, J. R., and Berchuck, A. Relationship between p21 expression and mutation of the P53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin. Cancer Res., 2: 1571-1575, 1996.
75. CIP1 in human colorectal carcinoma tissues and its association with P53 gene mutation. Int. J. Cancer, 69: 259-264, 1996.
76. Meng, R., Shi, H., Prabhu, N. S., George, D. L., and El-Deiry, W. S. Bypass of abnormal MDM2 inhibition of p53-dependent growth suppression. Clin. Cancer Res., 251-259, 1998.
77. Burke, L., Khan, M. A., Freedman, A., Guinee, D., Bennett, W. P., Caporaso, N. E., Fleming, M. V., Travis, W. D., Trastek, V., Pairolero, P. C., Tazelaar, H. F., Midthun, D., Liotta, L. A., and Harris, C. C. Allelic deletion analysis of the fragile histidine triad (FHIT) gene predicts poor survival in non-small cell lung cancer. Cancr Res., 58: in press, 1998.
78. Komiya, T., Hosono, Y., Hirashima, T., Masuda, N., Yasumitsu, T., Nakagawa, K., Kikui, M., Ohno, A., Fukuoka, M., and Kawase, I. p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin. Cancer Res., 3: 1831-1835, 1997.
79. waf1/cip1 mda-6 expression in non-small cell lung cancer: relationship to survival. Am. J. Respir. Cell Mol. Biol., 18: 213-217, 1998.